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The rise of SARS CoV-2 virus, a respiratory disease known
as COVID-19, has presented providers and patients with
unprecedented challenges regarding the prevention of
breast cancer. COVID-19 has significantly impacted preventative screenings, diagnostic tests and genetic counseling
both nationally and worldwide. Given the widespread concerns regarding employment, social distancing, and virus
exposure risk, many patients have reduced motivation to be
proactive in utilizing preventative services (Janda, 2020).
Researchers have predicted that these delays in screening
and diagnosis could lead to a significant increase in cancer-related deaths, displaying an urgent need to increase
preventative measures and employ risk reduction methods
for long-term care of breast cancer patients. Given that
early diagnosis has a significant impact on breast cancer
prognosis, an analysis of screening changes is essential in
navigating diagnostic regulations in the pandemic environment and assessing long-term repercussions of interruption of breast cancer diagnostics.
Nationally, multiple studies have revealed that breast cancer screening rates decreased amidst the lockdown period
of the COVID-19 pandemic. One cross sectional study
reported a 51.8% decrease in average weekly number of
newly diagnosed breast patients when comparing a baseline period (January 6, 2019 to February 29, 2020) to the
emergence of COVID-19 (March 1 to April 18, 2020)
(Kaufman, 2020). Furthermore, a US based survey
revealed 26.5% of 404 participants reported
deferred or cancelled breast cancer
service, of which the most commonly
impacted type was mammogram,
MRI, or ultrasound (Warner, 2020).
The decreased screening rates are likely
a result of both closures due to hospital COVID-19 regulations, as well as
altered health seeking behaviors to avoid
exposure to the virus. Researchers have
estimated that delayed screening could
lead to an excess of more than 30,000 cancer and multimorbidity deaths in the US,
suggesting an urgent need to plan for postpandemic increases in cancer incidence and
management (Lai, 2020).
The delay of breast cancer screening and followup poses significant risks to long-term breast
cancer management. Due to this emerging crisis, frequent patient monitoring as well as individualized follow-up plans are desperately needed.
Increased utilization of telehealth modalities can enable improved communication and frequency of follow-up
appointments and bolster the doctor-patient relationship,
while still maintaining adequate viral transmission precautions. The incorporation of hospital-provided private
transportation services for select patients could facilitate
increased accessibility for necessary in-person appointments. Some studies have also suggested that patients may
benefit from direct behavioral “nudging” from practitioners; for example, personalized reminders for screening
scheduling or incentives for influenza/COVID-19 vaccinations during diagnostic testing appointments (Janda,

2020). One study from Taiwan revealed a delayed decrease
in screening at mobile mammography visits compared
to hospital mammography, suggesting that utilization of
mobile units could increase screening rates (Peng, 2020).
While health providers can enable systemic changes to
improve cancer screening access and patient monitoring,
it is critical that they consider established risk stratification
schema, such as the one created by the American College
of Surgeons’ COVID-19 Breast Cancer Consortium, to
properly organize follow-up appointments in particularly
vulnerable populations.
It is essential for physicians and public health practitioners to recognize the ways in which existing cancer disparities could be exacerbated in the pandemic environment.
The COVID-19 pandemic has disproportionately affected
underserved and vulnerable populations, which may have
additional barriers, such as work conflicts, changes in
employment, and lack of daycare services for children,
that hinder utilization of screening services during the
pandemic (Carethers, 2020). Therefore, it is critical that
health professionals create outreach programs that can
incorporate extended screening hours, awareness for screening programs, and transportation to improve accessibility
for these populations. As vaccination efforts increase and
the public begins to resume regularly scheduled preventative care, healthcare providers must not only look
to improve cancer screenings, but
also focus on reaching out to vulnerable populations with missed
diagnostic tests to mitigate worsened prognosis.
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